Matritech detects NMP in early stage breast cancer:
This article was originally published in Clinica
The nuclear matrix protein NMP66 is present in the blood of women even at the earliest stages of breast cancer, a study by Matritech has revealed. The protein was found to be absent in the blood of normal women and in those with the benign breast disease fibroadenoma, therefore confirming the specificity of NMP66 to breast cancer at all stages of the disease, said the Newton, Massachusetts-based company. Matritech, whose NMP22 test kit for bladder cancer was cleared by the FDA in 1996, is currently developing a breast cancer test kit using NMP66 as a tumour marker.